PMID- 15468375
OWN - NLM
STAT- MEDLINE
DCOM- 20050721
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 31
IP  - 10
DP  - 2004 Oct
TI  - Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
PG  - 2055-61
AB  - OBJECTIVE: For many children enthesitis-related arthritis (ERA) causes 
      substantial morbidity, and conventional treatments frequently offer limited 
      efficacy. Tumor necrosis factor-alpha (TNF-alpha) has been found to play a 
      central role in the spondyloarthritides. We investigated the longterm efficacy of 
      the TNF fusion protein etanercept in the treatment of patients with ERA 
      refractory to disease modifying antirheumatic drug (DMARD) therapy. METHODS: 
      Eight patients with active, inflammatory ERA were treated in an open-label pilot 
      trial of twice weekly subcutaneous injections (dosing range of 25 to 37.5 mg 
      twice weekly, 0.2-0.8 mg/kg/dose) of etanercept for 2 years. Outcome measures 
      included duration of morning stiffness, active joint count, hemoglobin, and 
      erythrocyte sedimentation rate (ESR). Patients were permitted concomitant 
      nonsteroidal antiinflammatory drugs (NSAID) and DMARD at stable doses. RESULTS: 
      Treatment with etanercept resulted in significant improvement in active joint 
      count, hemoglobin, and ESR in all 8 patients within 2 months. Additionally, all 
      patients noted increased mobility and overall well being. Improvement in morning 
      stiffness did not achieve statistical significance. One patient was lost to 
      followup after completing one year of the study. The remaining 7 patients had 
      sustained statistically significant efficacy for active joint count, hemoglobin, 
      and ESR throughout the entire 2-year trial. All patients tolerated etanercept 
      with no side effects. CONCLUSION: Despite limited power, these results indicate 
      that etanercept provided a rapid clinical response in our cohort of patients with 
      refractory ERA, who achieved sustained efficacy over a 2-year period.
FAU - Henrickson, Michael
AU  - Henrickson M
AD  - Division of Rheumatology, Children's Hospital Central California, Madera, 
      California 93638-8762, USA. mhenrickson@childrenscentralcal.org
FAU - Reiff, Andreas
AU  - Reiff A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Recombinant Fusion Proteins)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Juvenile/*drug therapy/physiopathology
MH  - Child
MH  - Cohort Studies
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Male
MH  - Pilot Projects
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Spondylitis, Ankylosing/*drug therapy/physiopathology
MH  - Treatment Outcome
EDAT- 2004/10/07 09:00
MHDA- 2005/07/22 09:00
CRDT- 2004/10/07 09:00
PHST- 2004/10/07 09:00 [pubmed]
PHST- 2005/07/22 09:00 [medline]
PHST- 2004/10/07 09:00 [entrez]
AID - 0315162X-31-2055 [pii]
PST - ppublish
SO  - J Rheumatol. 2004 Oct;31(10):2055-61.